REGULATORY
Generic Approval Roster Includes at Least 3 AGs; Azilva, Revlimid, Maintate
At least three authorized generics (AGs) were among a throng of generics approved on February 15 towards generic listing in June. This includes AGs for the hypertension drug Azilva (azilsartan) and the blood cancer med Revlimid (lenalidomide). Azilva, an angiotensin…
To read the full story
Related Article
REGULATORY
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
- LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





